Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-11.15% $0.800
America/New_York / 24 apr 2024 @ 13:54
FUNDAMENTALS | |
---|---|
MarketCap: | 2.33 mill |
EPS: | -4.37 |
P/E: | -0.180 |
Earnings Date: | Apr 24, 2024 |
SharesOutstanding: | 2.91 mill |
Avg Daily Volume: | 0.0022 mill |
RATING 2024-04-24 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.180 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.180 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.04 (155.62%) $1.245 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
$ 0.747 - 0.853 ( +/- 6.63%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-08-01 | Biunno Jeffrey Francis | Buy | 26 203 | Common Stock |
2022-08-01 | Sarret Joseph J. | Buy | 131 017 | Common Stock |
2022-07-11 | Tozzo Stephanie | Buy | 200 000 | Stock Option (Right to buy) |
2022-07-11 | Tozzo Stephanie | Buy | 0 | |
2021-12-29 | Biunno Jeffrey Francis | Buy | 75 000 | Stock Option (Right to buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 7 451 858 | Sell: 253 700 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $0.800 (-11.15% ) |
Volume | 0.0004 mill |
Avg. Vol. | 0.0022 mill |
% of Avg. Vol | 16.29 % |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.